Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance
Correction(s) for this article
-
Correction to “Role and Regulation of Proapoptotic Bax in Oral Squamous Cell Carcinoma and Drug Resistance”
- Volume 47Issue 1Head & Neck
- pages: 414-417
- First Published online: October 21, 2024
Manzar Alam MSc
Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Search for more papers by this authorTanushree Kashyap MSc
Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Search for more papers by this authorPrajna Mishra MSc
Centre for Applied Chemistry, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Search for more papers by this authorAditya K. Panda PhD
Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Search for more papers by this authorSiddavaram Nagini PhD
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu, India
Search for more papers by this authorCorresponding Author
Rajakishore Mishra PhD
Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Correspondence
Rajakishore Mishra, Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ratu-Lohardaga Road, Brambe, Ranchi-835205, Jharkhand, India.
Email: [email protected]; [email protected]
Search for more papers by this authorManzar Alam MSc
Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Search for more papers by this authorTanushree Kashyap MSc
Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Search for more papers by this authorPrajna Mishra MSc
Centre for Applied Chemistry, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Search for more papers by this authorAditya K. Panda PhD
Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Search for more papers by this authorSiddavaram Nagini PhD
Department of Biochemistry and Biotechnology, Faculty of Science, Annamalai University, Annamalainagar, Tamil Nadu, India
Search for more papers by this authorCorresponding Author
Rajakishore Mishra PhD
Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ranchi, Jharkhand, India
Correspondence
Rajakishore Mishra, Centre for Life Sciences, School of Natural Sciences, Central University of Jharkhand, Ratu-Lohardaga Road, Brambe, Ranchi-835205, Jharkhand, India.
Email: [email protected]; [email protected]
Search for more papers by this authorFunding information: Department of Biotechnology, Ministry of Science and Technology, Grant/Award Number: BT/PR4624/MED/30/701/2012 BT/PR9028/INF/ 22/193/2013 (DBT BUILDER)
Abstract
Background
Bax, a proapoptotic protein but its regulation during oral cancer progression and resistance remains elusive.
Methods
A total of 127 samples including adjacent normal, primary tumor, and resistance to chemoradiation therapy (RCRT) samples from oral squamous cell carcinoma (OSCC) patients were used. The status of Bax was analyzed at DNA/mRNA/protein levels and the results were correlated with p53 and Akt expression in tissue samples/cisplatin-resistant oral tongue SCC (SCC9/SCC4-CisR) cell line.
Results
Frequent progressive decrease of Bax expression with infrequent promoter methylation, polymorphisms G(-248)A, and mutations was observed in OSCC progression/resistance. Furthermore, by targeting Akt pathway, induction of Bax-dependent cell death was observed and this was further enhanced with nimbolide treatment in SCC9/SCC4-CisR cells.
Conclusion
Hence, the Bax gene alteration and its deregulation through p53/Akt pathway are important for OSCC progression and drug resistance. Akt Inhibitor VIII and nimbolide synergistically induce Bax, and it is therefore beneficial for chemosensitizing cisplatin-resistant human OSCC.
CONFLICT OF INTEREST
The authors declare that they have no conflicts of interest with the contents of this article.
Supporting Information
| Filename | Description |
|---|---|
| hed25471-sup-0001-TableS1.docxWord 2007 document , 29.6 KB |
Supporting Information S1 List of primers and PCR conditions used to detect methylation of Bax gene promoter by MS-PCR S2. List of primers and PCR conditions used for detecting mutation of different Bax exons 1–6 by SSCP-PCR S3. Primer sequence of Bax and GAPDH for RT-PCR analysis |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-E386.
- 2Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8): 573-584.
- 3Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol. 2007; 4(2): 86-100.
- 4Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol. 1997; 139(5): 1281-1292.
- 5Liu MD, Xiong SJ, Tan F, Liu Y. Physcion 8-O-beta-glucopyranoside induces mitochondria-dependent apoptosis of human oral squamous cell carcinoma cells via suppressing survivin expression. Acta Pharmacol Sin. 2016; 37(5): 687-697.
- 6Su CC, Lee KI, Chen MK, Kuo CY, Tang CH, Liu SH. Cantharidin induced oral squamous cell carcinoma cell apoptosis via the JNK-regulated mitochondria and endoplasmic reticulum stress-related signaling pathways. PLoS One. 2016; 11(12): e0168095.
- 7Manoochehri M, Karbasi A, Bandehpour M, Kazemi B. Down-regulation of BAX gene during carcinogenesis and acquisition of resistance to 5-FU in colorectal cancer. Pathol Oncol Res. 2014; 20(2): 301-307.
- 8Hassan M, Watari H, AbuAlmaaty A, Ohba Y, Sakuragi N. Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014; 2014: 150845.
- 9Camisasca DR, Honorato J, Bernardo V, et al. Expression of Bcl-2 family proteins and associated clinicopathologic factors predict survival outcome in patients with oral squamous cell carcinoma. Oral Oncol. 2009; 45(3): 225-233.
- 10Kato K, Kawashiri S, Yoshizawa K, Kitahara H, Yamamoto E. Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas. J Oral Pathol Med. 2008; 37(6): 364-371.
- 11Zhang M, Zhang P, Zhang C, et al. Prognostic significance of Bcl-2 and Bax protein expression in the patients with oral squamous cell carcinoma. J Oral Pathol Med. 2009; 38(3): 307-313.
- 12Wei MC, Zong WX, Cheng EH, et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science. 2001; 292(5517): 727-730.
- 13LeBlanc H, Lawrence D, Varfolomeev E, et al. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat Med. 2002; 8(3): 274-281.
- 14Miquel C, Borrini F, Grandjouan S, et al. Role of bax mutations in apoptosis in colorectal cancers with microsatellite instability. Am J Clin Pathol. 2005; 123(4): 562-570.
- 15Moshynska O, Sankaran K, Saxena A. Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia. Mol Pathol. 2003; 56(4): 205-209.
- 16Chen K, Hu Z, Wang LE, et al. Single-nucleotide polymorphisms at the TP53-binding or responsive promoter regions of BAX and BCL2 genes and risk of squamous cell carcinoma of the head and neck. Carcinogenesis. 2007; 28(9): 2008-2012.
- 17Saxena A, Moshynska O, Sankaran K, Viswanathan S, Sheridan DP. Association of a novel single nucleotide polymorphism, G(-248)A, in the 5'-UTR of BAX gene in chronic lymphocytic leukemia with disease progression and treatment resistance. Cancer Lett. 2002; 187(1–2): 199-205.
- 18Moshynska O, Moshynskyy I, Misra V, Saxena A. G125A single-nucleotide polymorphism in the human BAX promoter affects gene expression. Oncogene. 2005; 24(12): 2042-2049.
- 19Shen H, Liu L, Yang Y, Xun W, Wei K, Zeng G. Betulinic acid inhibits cell proliferation in human oral squamous cell carcinoma via modulating ROS-regulated p53 signaling. Oncol Res. 2017; 25: 1141-1152.
- 20Henriksson E, Baldetorp B, Borg A, et al. p53 mutation and cyclin D1 amplification correlate with cisplatin sensitivity in xenografted human squamous cell carcinomas from head and neck. Acta Oncol. 2006; 45(3): 300-305.
- 21Sakuragi N, Salah-eldin AE, Watari H, et al. Bax, Bcl-2, and p53 expression in endometrial cancer. Gynecol Oncol. 2002; 86(3): 288-296.
- 22Miyashita T, Krajewski S, Krajewska M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 1994; 9(6): 1799-1805.
- 23Strober W, Kelsall B, Fuss I, et al. Reciprocal IFN-gamma and TGF-beta responses regulate the occurrence of mucosal inflammation. Immunol Today. 1997; 18(2): 61-64.
- 24Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2(7): 489-501.
- 25Yu Z, Weinberger PM, Sasaki C, et al. Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol Biomarkers Prev. 2007; 16(3): 553-558.
- 26Lim J, Kim JH, Paeng JY, et al. Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol. 2005; 58(11): 1199-1205.
- 27Kim KR, Park KK, Chung WY, Hwang YS. The inhibitory effect of buddlejasaponin IV on the growth of YD-10B human oral squamous cell carcinoma cells. J Cancer Prev. 2013; 18(4): 330-336.
- 28Kiyoshima T, Yoshida H, Wada H, et al. Chemoresistance to concanamycin A1 in human oral squamous cell carcinoma is attenuated by an HDAC inhibitor partly via suppression of Bcl-2 expression. PLoS One. 2013; 8(11): e80998.
- 29Iamaroon A, Krisanaprakornkit S. Overexpression and activation of Akt2 protein in oral squamous cell carcinoma. Oral Oncol. 2009; 45(10): e175-e179.
- 30Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science. 2000; 290(5493): 989-992.
- 31Bose P, Klimowicz AC, Kornaga E, et al. Bax expression measured by AQUAnalysis is an independent prognostic marker in oral squamous cell carcinoma. BMC Cancer. 2012; 12: 332.
- 32Farnebo L, Jedlinski A, Ansell A, et al. Proteins and single nucleotide polymorphisms involved in apoptosis, growth control, and DNA repair predict cisplatin sensitivity in head and neck cancer cell lines. Int J Mol Med. 2009; 24(4): 549-556.
- 33Sophia J, Kiran Kishore TK, Kowshik J, Mishra R, Nagini S. Nimbolide, a neem limonoid inhibits phosphatidyl inositol-3 kinase to activate glycogen synthase kinase-3beta in a hamster model of oral oncogenesis. Sci Rep. 2016; 6: 22192.
- 34Chien SY, Hsu CH, Lin CC, et al. Nimbolide induces apoptosis in human nasopharyngeal cancer cells. Environ Toxicol. 2017; 32: 2085-2092.
- 35Alam M, Kashyap T, Pramanik KK, Singh AK, Nagini S, Mishra R. The elevated activation of NFkappaB and AP-1 is correlated with differential regulation of Bcl-2 and associated with oral squamous cell carcinoma progression and resistance. Clin Oral Investig. 2017; 21: 2721-2731.
- 36Pramanik KK, Singh AK, Alam M, et al. Reversion-inducing cysteine-rich protein with Kazal motifs and its regulation by glycogen synthase kinase 3 signaling in oral cancer. Tumour Biol. 2016; 37(11): 15253-15264.
- 37Bae YK, Brown A, Garrett E, et al. Hypermethylation in histologically distinct classes of breast cancer. Clin Cancer Res. 2004; 10(18 Pt 1): 5998-6005.
- 38Peng H, Aiello A, Packham G, Isaacson PG, Pan L. Infrequent bax gene mutations in B-cell lymphomas. J Pathol. 1998; 186(4): 378-382.
10.1002/(SICI)1096-9896(199812)186:4<378::AID-PATH203>3.0.CO;2-5 CAS PubMed Web of Science® Google Scholar
- 39Loro LL, Johannessen AC, Vintermyr OK. Loss of BCL-2 in the progression of oral cancer is not attributable to mutations. J Clin Pathol. 2005; 58(11): 1157-1162.
- 40Chou D, Miyashita T, Mohrenweiser HW, et al. The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet Cytogenet. 1996; 88(2): 136-140.
- 41Winder DM, Ball SL, Vaughan K, et al. Sensitive HPV detection in oropharyngeal cancers. BMC Cancer. 2009; 9: 440.
- 42Mishra R. Biomarkers of oral premalignant epithelial lesions for clinical application. Oral Oncol. 2012; 48(7): 578-584.
- 43Teni T, Pawar S, Sanghvi V, Saranath D. Expression of bcl-2 and bax in chewing tobacco-induced oral cancers and oral lesions from India. Pathol Oncol Res. 2002; 8(2): 109-114.
- 44Ionov Y, Yamamoto H, Krajewski S, Reed JC, Perucho M. Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution. Proc Natl Acad Sci U S A. 2000; 97(20): 10872-10877.
- 45Sturm I, Papadopoulos S, Hillebrand T, et al. Impaired BAX protein expression in breast cancer: mutational analysis of the BAX and the p53 gene. Int J Cancer. 2000; 87(4): 517-521.
- 46Kholoussi NM, El-Nabi SE, Esmaiel NN, Abd El-Bary NM, El-Kased AF. Evaluation of Bax and Bak gene mutations and expression in breast cancer. Biomed Res Int. 2014; 2014: 249372.
- 47Abdel-Rahman WM, Georgiades IB, Curtis LJ, Arends MJ, Wyllie AH. Role of BAX mutations in mismatch repair-deficient colorectal carcinogenesis. Oncogene. 1999; 18(12): 2139-2142.
- 48Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995; 80(2): 293-299.
- 49Raju SC, Hauff SJ, Lemieux AJ, et al. Combined TP53 mutation/3p loss correlates with decreased radiosensitivity and increased matrix-metalloproteinase activity in head and neck carcinoma. Oral Oncol. 2015; 51(5): 470-475.
- 50Ji S, Shao G, Lv X, et al. Downregulation of miRNA-128 sensitises breast cancer cell to chemodrugs by targeting Bax. Cell Biol Int. 2013; 37(7): 653-658.
- 51Yang J, Li J, Le Y, Zhou C, Zhang S, Gong Z. PFKL/miR-128 axis regulates glycolysis by inhibiting AKT phosphorylation and predicts poor survival in lung cancer. Am J Cancer Res. 2016; 6(2): 473-485.
- 52Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8): 627-644.
- 53Donzelli S, Fontemaggi G, Fazi F, et al. MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ. 2012; 19(6): 1038-1048.
- 54Bundela S, Sharma A, Bisen PS. Potential compounds for oral cancer treatment: resveratrol, nimbolide, lovastatin, bortezomib, vorinostat, berberine, pterostilbene, deguelin, andrographolide, and colchicine. PLoS One. 2015; 10(11): e0141719.
Citing Literature
